| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.70▼ | 4.69▼ | 4.67▲ | 4.73▼ | 4.83▼ |
| MA10 | 4.71▼ | 4.66▲ | 4.70▼ | 4.59▲ | 6.12▼ |
| MA20 | 4.71▼ | 4.69▼ | 4.73▼ | 4.80▼ | 6.20▼ |
| MA50 | 4.67▲ | 4.71▼ | 4.72▼ | 6.19▼ | 4.91▼ |
| MA100 | 4.69▼ | 4.68▼ | 4.58▲ | 6.17▼ | 6.70▼ |
| MA200 | 4.73▼ | 4.63▲ | 5.30▼ | 5.30▼ | 10.42▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | 0.006▲ | -0.008▼ | 0.098▲ | -0.343▼ |
| RSI | 44.969▼ | 47.922▼ | 48.090▼ | 38.966▼ | 43.270▼ |
| STOCH | 23.141 | 60.874 | 31.572 | 69.365 | 15.945▼ |
| WILL %R | -100.000▼ | -52.500 | -58.696 | -36.190 | -86.837▼ |
| CCI | -124.304▼ | 45.297 | -6.598 | 36.346 | -81.895 |
|
Friday, July 11, 2025 01:21 PM
The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...
|
|
Tuesday, July 08, 2025 04:29 AM
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to ...
|
|
Monday, July 07, 2025 09:30 PM
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/07/25 | 4.72 | 4.75 | 4.58 | 4.68 | 1,207,800 |
| 10/07/25 | 4.82 | 4.82 | 4.63 | 4.74 | 1,592,300 |
| 09/07/25 | 4.77 | 4.90 | 4.65 | 4.81 | 1,973,800 |
| 08/07/25 | 4.71 | 4.77 | 4.60 | 4.71 | 1,375,900 |
| 07/07/25 | 4.72 | 4.93 | 4.6886 | 4.69 | 2,172,062 |
| 03/07/25 | 4.87 | 4.9836 | 4.66 | 4.80 | 1,675,023 |
| 02/07/25 | 4.31 | 5.06 | 4.21 | 4.85 | 5,315,100 |
| 01/07/25 | 4.16 | 4.53 | 4.09 | 4.29 | 2,720,500 |
| 30/06/25 | 4.15 | 4.23 | 4.01 | 4.15 | 2,366,700 |
| 27/06/25 | 4.14 | 4.29 | 4.04 | 4.15 | 4,272,967 |
|
|
||||
|
|
||||
|
|